Combination therapy treats leishmaniasis, HIV patients

Coinfection with visceral leishmaniasis (VL) and human immunodeficiency virus (HIV) has been observed in at least 35 countries on four continents and requires special case management. Currently, the World Health Organization recommends AmBisome monotherapy for treatment. Now, researchers have showed that a combination therapy of AmBisome and miltefosine is more effective.